



Group VI iPLA2 Polyclonal Antibody

| | |
|---------------------------|---|
| Catalog No | YP-Ab-02648 |
| Isotype | IgG |
| Reactivity | Human;Mouse;Rat |
| Applications | WB;ELISA |
| Gene Name | PLA2G6 |
| Protein Name | 85/88 kDa calcium-independent phospholipase A2 |
| Immunogen | Synthesized peptide derived from the Internal region of human Group VI iPLA2. |
| Specificity | Group VI iPLA2 Polyclonal Antibody detects endogenous levels of Group VI iPLA2 protein. |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Source | Polyclonal, Rabbit,IgG |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Dilution | Western Blot: 1/500 - 1/2000. ELISA: 1/5000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Purity | ≥90% |
| Storage Stability | -20°C/1 year |
| Synonyms | PLA2G6; PLPLA9; 85/88 kDa calcium-independent phospholipase A2; Cal-PLA2; Group VI phospholipase A2; GVI PLA2; Intracellular membrane-associated calcium-independent phospholipase A2 beta; iPLA2-beta; Patatin-like phospholipase domain-contai |
| Observed Band | 90kD |
| Cell Pathway | Cytoplasm . Cell membrane . Mitochondrion . Cell projection, pseudopodium . Recruited to the membrane-enriched pseudopods upon MCP1/CCL2 stimulation in monocytes. . |
| Tissue Specificity | Four different transcripts were found to be expressed in a distinct tissue distribution. |
| Function | catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,disease:Defects in PLA2G6 are a cause of neurodegeneration with brain iron accumulation (NBIA) [MIM:610217]. NBIA comprises a clinically and genetically heterogeneous group of disorders with high basal ganglia iron.,disease:Defects in PLA2G6 are the cause of infantile neuroaxonal dystrophy 1 (INAD1) [MIM:256600]; also known as Seitelberger disease. Infantile neuroaxonal dystrophy (INAD) is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years.,disease:Defects in PLA2G6 are the cause of Karak syndrome [MIM:608395]. Karak syndrome is a |



neurologic disease characterized by early-onset progressive cerebellar ataxia, dystonia, spasticity, intellectual and features c

Background

The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010],

matters needing attention

Avoid repeated freezing and thawing!

Usage suggestions

This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images